Queen Mary Hospital
Hong Kong, 00000
Location status: Recruiting
Location contact
Man Him, Matrix Fung, MBBS
CONTACT
Man Him, Matrix Fung, MBBS
PRINCIPAL_INVESTIGATOR
NCT Number: NCT06426563
Thyroid nodule is a common condition that affects up to 60% of the population. There is an estimated 10% lifetime probability of developing a thyroid nodule. Although most thyroid nodules are benign, up to 10-15% can enlarge to cause compressive symptoms including neck pressure and discomfort, dysphagia, dyspnea, and dysphonia. The conventional treatment for these benign but problematic nodules has been thyroidectomy. Although generally a low risk operation, thyroidectomy is associated with some risk for recurrent laryngeal nerve injury, bleeding, infection, and need for thyroid hormone supplementation. Since the early 2000s, ultrasound-guided percutaneous thermal ablation has emerged as a potential alternative treatment to surgery for benign thyroid nodules. Of the myriad ablation methods, the most commonly used techniques are radiofrequency ablation (RFA) and microwave ablation (MWA). [1-3] A growing body of evidence shows that RFA is an effective treatment for benign solid thyroid nodules, toxic adenomas, and thyroid cysts resulting in overall volume reduction ranges of 40-80% at 1 year, with durable resolution of compressive and hyperthyroid symptoms. However, RFA is not without its limitations. Radiofrequency waves can be limited by the heat sink effect and tissue char leading to longer procedure times and potentially less optimal outcomes in larger, hypervascular, and/or more cystic nodules.
Microwave ablation (MWA) is another ablative technique that uses electromagnetic energy waves to cause tissue hyperthermia and coagulative necrosis. It generally causes higher ablation temperatures than RFA and is less subject to the heat sink effect, and therefore can facilitate more efficient ablation procedures. Current evidence comparing RFA versus MWA for thyroid ablation was limited and was either retrospective, non-randomized [4-9], under-powered, or with an unequal baseline. The results from these studies were also conflicting, suggesting suboptimal quality of evidence and bias due to non-standardized technique of ablation across studies. To date, there is no randomized controlled trial comparing the efficacy and safety of RFA versus MWA for the treatment of benign thyroid nodules. Given the higher ablation temperatures, freedom from heat sink effect, and no influence from impedance changes during ablation, MWA may achieve different treatment efficacy.
Interested in participating?
Request Info18 year and older
All sexes
Interventional
Not applicable
Hong Kong, 00000
Location status: Recruiting
Man Him, Matrix Fung, MBBS
CONTACT
Man Him, Matrix Fung, MBBS
PRINCIPAL_INVESTIGATOR
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Use Radiofrequency or Microwave ablation device to treat thyroid nodule
Time frame: 12 months
Time frame: 12-24 months
Time frame: 12-24 months
Time frame: 12-24 months
To measure cosmetic score from 1 to 4 (1 is No palpable goitre, 2 is Palpable goitre but invisible, 3 is Goitre only visible to experienced clinician, 4 is Easily visible goitre)
Time frame: 12-24 months
compressive symptom score from 0 (no compression feeling) to 100 (the most compressive)
Time frame: 12-24 months
Swallowing Impairment Index (SIS-6) is an assessment tool about swallowing dysfunction and symptom. It comprises six question items ranging from 0 (no impairment) to 24 (maximum impairment)
Time frame: 12-24 months
0 is no pain, 10 is the most painful
Time frame: 12-24 months
SF-12(v2) is an assessment tool about quality of life. It comprises 12 question items ranging from 11 (worst quality of life) to 56 (best quality of life).
Contact information is provided by the study sponsor or research team.
The University of Hong Kong
Other
Microwave Ablation Versus Radiofrequency Ablation for the Treatment of Moderate-sized Benign Thyroid Nodules, a Randomized Controlled Trial
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07046546
Autoimmune Diseases, Endocrine Gland Neoplasms
Reading, United Kingdom
View Trial DetailsNCT06729762
Endocrine Gland Neoplasms, Endocrine System Diseases
Beijing, Beijing Municipality, China
View Trial DetailsNCT06779747
Endocrine Gland Neoplasms, Endocrine System Diseases
Bologna, Italy
View Trial DetailsNCT04666103
Ablation; Retina, Endocrine Gland Neoplasms
Wuhan, Hubei, China
View Trial Details